{"title":"从卵巢癌早期到晚期,MHC I类分子(HLA-A、-B、-C、-E、-F、-G和-J)的表达减少","authors":"Caglar Berkel","doi":"10.1111/aji.70154","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Problem</h3>\n \n <p>Interferon-ε (IFNε), which is highly abundant in the epithelium of the female reproductive tract (FRT), is a recently identified tumor suppressor for ovarian cancer. IFNε induces the expression of certain HLA class I family members in HGSOC (high-grade serous ovarian cancer), and its expression is lost during ovarian tumorigenesis. However, tumor stage–dependent expression of HLA class I family members in ovarian cancer has not been previously studied.</p>\n </section>\n \n <section>\n \n <h3> Method of Study</h3>\n \n <p>Data analysis and visualization were performed using various gene expression and transcriptomics datasets in the R statistical programming environment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We found that the expression of HLA-A, -B, -C, -E, -F, -G, and -J is lower in late stage ovarian tumors compared to early-stage tumors. The total expression of HLA class I family members decreases with age in ovarian cancer. Furthermore, we showed that the expression of some IFN-regulated genes, which were shown to be upregulated by IFNε, decreases from early to late stage in ovarian cancer, in parallel to the loss of IFNε expression in ovarian tumorigenesis and possibly in tumor progression. We also found that breast tumors (another hormonally driven cancer) with positive progesterone receptor status have lower IFNε mRNA expression compared to those with negative PR status. Besides, we reported that breast tumors with positive estrogen receptor (ER) status have lower expression of IFNε compared to those with negative ER status.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Combined, this study points that the decrease in the expression of IFNε, HLAs, or some other IFNε-regulated genes during ovarian cancer progression might contribute to worse prognosis in advanced disease.</p>\n </section>\n </div>","PeriodicalId":7665,"journal":{"name":"American Journal of Reproductive Immunology","volume":"94 3","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expression of MHC Class I Molecules (HLA-A, -B, -C, -E, -F, -G, and -J) Decreases From Early to Late Stage in Ovarian Cancer\",\"authors\":\"Caglar Berkel\",\"doi\":\"10.1111/aji.70154\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Problem</h3>\\n \\n <p>Interferon-ε (IFNε), which is highly abundant in the epithelium of the female reproductive tract (FRT), is a recently identified tumor suppressor for ovarian cancer. IFNε induces the expression of certain HLA class I family members in HGSOC (high-grade serous ovarian cancer), and its expression is lost during ovarian tumorigenesis. However, tumor stage–dependent expression of HLA class I family members in ovarian cancer has not been previously studied.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Method of Study</h3>\\n \\n <p>Data analysis and visualization were performed using various gene expression and transcriptomics datasets in the R statistical programming environment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We found that the expression of HLA-A, -B, -C, -E, -F, -G, and -J is lower in late stage ovarian tumors compared to early-stage tumors. The total expression of HLA class I family members decreases with age in ovarian cancer. Furthermore, we showed that the expression of some IFN-regulated genes, which were shown to be upregulated by IFNε, decreases from early to late stage in ovarian cancer, in parallel to the loss of IFNε expression in ovarian tumorigenesis and possibly in tumor progression. We also found that breast tumors (another hormonally driven cancer) with positive progesterone receptor status have lower IFNε mRNA expression compared to those with negative PR status. Besides, we reported that breast tumors with positive estrogen receptor (ER) status have lower expression of IFNε compared to those with negative ER status.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Combined, this study points that the decrease in the expression of IFNε, HLAs, or some other IFNε-regulated genes during ovarian cancer progression might contribute to worse prognosis in advanced disease.</p>\\n </section>\\n </div>\",\"PeriodicalId\":7665,\"journal\":{\"name\":\"American Journal of Reproductive Immunology\",\"volume\":\"94 3\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Reproductive Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/aji.70154\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Reproductive Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aji.70154","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Expression of MHC Class I Molecules (HLA-A, -B, -C, -E, -F, -G, and -J) Decreases From Early to Late Stage in Ovarian Cancer
Problem
Interferon-ε (IFNε), which is highly abundant in the epithelium of the female reproductive tract (FRT), is a recently identified tumor suppressor for ovarian cancer. IFNε induces the expression of certain HLA class I family members in HGSOC (high-grade serous ovarian cancer), and its expression is lost during ovarian tumorigenesis. However, tumor stage–dependent expression of HLA class I family members in ovarian cancer has not been previously studied.
Method of Study
Data analysis and visualization were performed using various gene expression and transcriptomics datasets in the R statistical programming environment.
Results
We found that the expression of HLA-A, -B, -C, -E, -F, -G, and -J is lower in late stage ovarian tumors compared to early-stage tumors. The total expression of HLA class I family members decreases with age in ovarian cancer. Furthermore, we showed that the expression of some IFN-regulated genes, which were shown to be upregulated by IFNε, decreases from early to late stage in ovarian cancer, in parallel to the loss of IFNε expression in ovarian tumorigenesis and possibly in tumor progression. We also found that breast tumors (another hormonally driven cancer) with positive progesterone receptor status have lower IFNε mRNA expression compared to those with negative PR status. Besides, we reported that breast tumors with positive estrogen receptor (ER) status have lower expression of IFNε compared to those with negative ER status.
Conclusions
Combined, this study points that the decrease in the expression of IFNε, HLAs, or some other IFNε-regulated genes during ovarian cancer progression might contribute to worse prognosis in advanced disease.
期刊介绍:
The American Journal of Reproductive Immunology is an international journal devoted to the presentation of current information in all areas relating to Reproductive Immunology. The journal is directed toward both the basic scientist and the clinician, covering the whole process of reproduction as affected by immunological processes. The journal covers a variety of subspecialty topics, including fertility immunology, pregnancy immunology, immunogenetics, mucosal immunology, immunocontraception, endometriosis, abortion, tumor immunology of the reproductive tract, autoantibodies, infectious disease of the reproductive tract, and technical news.